Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells

Yutaka Hattori; Takumi Futo; Ryo Uozaki; Daiju Ichikawa; Takashi Yamaguchi; Tomofumi Yamamoto; Maiko Matsushita; Maki Hirao

doi:10.1007/s12185-022-03297-w

Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells

Yutaka Hattori, Takumi Futo, Ryo Uozaki, Daiju Ichikawa, Takashi Yamaguchi, Tomofumi Yamamoto, Maiko Matsushita, Maki Hirao

School of Pharmacy

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	605-608
Number of pages	4
Journal	International journal of hematology
Volume	115
Issue number	4
DOIs	https://doi.org/10.1007/s12185-022-03297-w
Publication status	Published - 2022 Apr

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s12185-022-03297-w

Cite this

@article{82408cb996e946f0a6952fd796b675fc,

title = "Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells",

author = "Yutaka Hattori and Takumi Futo and Ryo Uozaki and Daiju Ichikawa and Takashi Yamaguchi and Tomofumi Yamamoto and Maiko Matsushita and Maki Hirao",

note = "Funding Information: We thank Professor Takemi Otsuki (Kawasaki Medical School, Kurashiki, Japan) for the kind gift of MM cell lines. This work was supported in part by Grants-in-Aid for Scientific Research, # 20K08763 and #17K09940 (both Y.H.) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Y.H.), grants-in-aid from the Translational Research Network Program of Japan Agency for Medical Research and Development (AMED) #15lm0103010j0002 and #16lm0103010j0003 (both Y.H.) and the Japanese Society of Hematology Research Grant (Y.H.). Funding Information: The authors of this manuscript have the following conflicts of interests: research grants from Takeda Pharmaceutical Company (Y.H.), MSD (Y.H.), Astellas Pharma Inc. (Y.H.), Daiichi Sankyo Co. LD (Y.H.), Pfizer Inc. (Y.H.), Ono Pharmaceutical Co. LD (Y.H.). ",

year = "2022",

month = apr,

doi = "10.1007/s12185-022-03297-w",

language = "English",

volume = "115",

pages = "605--608",

journal = "International journal of hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells

AU - Hattori, Yutaka

AU - Futo, Takumi

AU - Uozaki, Ryo

AU - Ichikawa, Daiju

AU - Yamaguchi, Takashi

AU - Yamamoto, Tomofumi

AU - Matsushita, Maiko

AU - Hirao, Maki

N1 - Funding Information: We thank Professor Takemi Otsuki (Kawasaki Medical School, Kurashiki, Japan) for the kind gift of MM cell lines. This work was supported in part by Grants-in-Aid for Scientific Research, # 20K08763 and #17K09940 (both Y.H.) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Y.H.), grants-in-aid from the Translational Research Network Program of Japan Agency for Medical Research and Development (AMED) #15lm0103010j0002 and #16lm0103010j0003 (both Y.H.) and the Japanese Society of Hematology Research Grant (Y.H.). Funding Information: The authors of this manuscript have the following conflicts of interests: research grants from Takeda Pharmaceutical Company (Y.H.), MSD (Y.H.), Astellas Pharma Inc. (Y.H.), Daiichi Sankyo Co. LD (Y.H.), Pfizer Inc. (Y.H.), Ono Pharmaceutical Co. LD (Y.H.).

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85125108241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125108241&partnerID=8YFLogxK

U2 - 10.1007/s12185-022-03297-w

DO - 10.1007/s12185-022-03297-w

M3 - Letter

C2 - 35194739

AN - SCOPUS:85125108241

SN - 0925-5710

VL - 115

SP - 605

EP - 608

JO - International journal of hematology

JF - International journal of hematology

IS - 4

ER -

Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this